Absence of DNA adduct in the leukocytes from breast cancer patients treated with toremifene

Chemical Research in Toxicology

Volumn 19, Issue 3, 2006, Pages 421-425

  Umemoto, Atsushi ^a   Lin, Chun Xing ^a   Ueyama, Yuji ^a   Komaki, Kansei ^a   Laxmi, Y R Santosh ^b   Shibutani, Shinya ^b  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DNA; DOXIFLURIDINE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PHOSPHORUS 32; TAMOXIFEN; TOREMIFENE; UFT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CARCINOGENICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DNA EXTRACTION; DOSE RESPONSE; DRUG SAFETY; DRUG STRUCTURE; ENDOMETRIUM CANCER; GENOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; ISOTOPE LABELING; LEUKOCYTE; LIVER CANCER; NONHUMAN; RAT; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA ADDUCTS; DNA, NEOPLASM; FEMALE; HUMANS; LEUKOCYTES; MIDDLE AGED; TOREMIFENE;

EID: 33645463254     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx0503045     Document Type: Article

References (50)

1. Jordan, V. C. (1994) The development of tamoxifen for breast cancer therapy. In Long-Term Tamoxifen Treatment for Breast Cancer (Jordan, V. C., Ed.) pp 3-26, University of Wisconsin Press, Madison.
2. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1996) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 66, Some Pharmaceutical Drugs, IARC Scientific Publications, Lyon.
3. Fisher, B., Constantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. (1998) Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90, 1371-1388.
4. Powles, T., Eeles, R., Ashley, S., Easton, D., Chang, J., Dowsett, M., Tidy, A., Viggers, J., and Davey, J. (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352, 98-101.
5. Rutqvist, L. E., Johansson, H., Signomklao, T., Johansson, U., Fornander, T., and Willing, N. (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignacies. Stockholm Breast Cancer Study Group. J. Natl. Cancer Inst. 87, 645-651.
6. Greaves, P., Goonetilleke, R., Nunn, G., Topham, J., and Orton, T. (1993) Two-year carcinogenecity study of tamoxifen in Alderley Park Wister-derived rats. Cancer Res. 53, 3919-3924.
7. Hard, G. C., Iatropoulos, M. J., Jordan, K., Radi, L., Kaltenberg, O. P., Imondi, A. R., and Williams, G. M. (1993) Major difference in the hepatocarcinogenecity and DNA adduct froming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res. 53, 4534-4541.
8. Kuiper, G. G., Carlsson, B., Grandien, K., Enmark, E., Häggblad, J., Nilsson, S., and Gustafsson, J. A. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138, 863-870.
9. Li, D., Dragan, Y., Jordan, V. C., Wang, M., and Pilot, H. C. (1997) Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Cancer Res. 57, 1438-1441.
10. Rajaniemi, H., Rasanen, I., Koivisto, P., Peltonen, K., and Hemminki, K. (1999) Identification of the major tamoxifen-DNA adducts in rats liver by mass spectroscopy. Carcinogenesis 20, 305-309.
11. 2- deoxyguanosinyl)tamoxifen N-oxide. Carcinogenesis 21, 1737-1744.
12. Umemoto, A., Komaki, K., Monden, Y., Suwa, M., Kanno, Y., Kitagawa, M., Suzuki, M., Lin, C., Ueyama, Y., Momen, M. A., Ravindernath, A., and Shibutani, S. (2001) Identification and quantification of tamoxifen-DNA adducts in the liver of rats and mice. Chem. Res. Toxicol. 14, 1006-1013.
13. Buzdar, A., and Hortobagyi, G. N. (1998) Tamoxifen and toremifene in breast cancer comparison of safety and efficacy. J. Clin. Oncol. 16, 348-353.
14. O'Regan, R. M., Cisneros, A., England, G. M., MacGregor, J. I., Muenzner, H. D., Assikis, V. J., Bilimoria, M. M., Piette, M., Dragan, Y. P., Pitot, H. C., Chatterton, R., and Jordan, V. C. (1998) Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J. Natl. Cancer Inst. 90, 1552-1558.
15. Kangas, L. Review of the pharmacological properties of toremifene. (1990) J. Steroid Biochem. 36, 191-195.
16. Tomas, E., Kauppila, A., Blanco, G., Apaja-Sarkkinen, M., and Laatikainen, T. (1995) Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol. Oncol. 59, 261-266.
17. Hard, G. C., Iatropoulos, M. J., Jordan, K., Radi, L., Kaltenberg, O. P., Imondi, A. R., and Williams, G. M. (1993) Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res. 53, 4534-4541.
18. White, I. N. H., de Matteis, F., Davies, A., Smith, L. L., Crofton-Sleigh, C., Venitt, S., Hewer, A., and Phillips, D. H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57B1/6 mice, and in human MCL-5 cells. Carcinogenesis 13, 2197-2203.
19. Li, D., Dragan, Y., Jordan, V. C., Wang, M., and Pitot, H. C. (1997) Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Cancer Res. 57, 1438-1441.
20. Bergman, L., Beelen, M. L., Gallee, M. P., Hollema, H., Benraadt, J., van Leeuwen, F. E., and the Comprehensive Cancer Centres' ALERT Group (2000) Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 356, 881-887.
21. Hachisuga, T., Tsujioka, H., Horiuchi, S., Udou, T., Emoto, M., and Kawarabayashi, T. (2005) K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene. Br. J. Cancer 92, 1098-1103.
22. Davies, R., Gant, T. W., Smith, L. L., and Styles, J. A. (1999) Tamoxifen induces G:C→T:A mutations in the cll gene in the liver of lambda/lacI transgenic rats but not at 5′-CpG-3′ dinucleotide sequences as found in the lacI transgene. Carcinogenesis 20, 1351-1356.
23. da Costa, G. G., Manjanatha, M. G., Marques, M. M., and Beland, F. A. (2002) Induction of lacI mutations in Big Blue rats treated with tamoxifen and α-hydroxytamoxifen. Cancer lett. 176, 37-45.
24. 2-Deoxyguanosinyl)tamoxifen. Biochemistry 36, 13010-13017.
25. 2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res. 59, 2091-2095.
26. Stygar, D., Muravitskaya, N., Eriksson, B., Eriksson, H., and Sahlin, L. (2003) Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus. Reprod. Biol. Endocrinol. 1, 1-8.
27. 32P-postlabeling. Cancer Res. 59, 4829-4833.
28. da Costa, G. G., McDaniel-Hamilton, L. P., Heflich, R. H., Marques, M. M., and Beland, F. A. (2001) DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives. Carcinogenesis 22, 1307-1315.
29. Kim, S. Y., Suzuki, N., Santosh Laxmi, Y. R., and Shibutani, S. (2006) Inefficient repair of tamoxifen-DNA adducts in rats and mice. Drug Metab. Dispos. 34, 311-317.
30. Shibutani, S., Reardon, J. T., Suzuki, N., and Sancar, A. (2000) Excision of tamoxifen-DNA adducts by the human nucleotide excision repair system. Cancer Res. 60, 2607-2610.
31. Shibutani, S., Suzuki, N., Terashima, I., Sugarman, M. S., Grollman, A. P., and Pearl, M. L. (1999) Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem. Res. Toxicol. 12, 646-653.
32. Shibutani, S., Ravindernath, A., Suzuki, N., Terashima, I., Sugarman, S. M., Grollman, A. P., and Pearl, M. L. (2000) Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 21, 1461-1467.
33. Martin, E. A., Brown, K., Gaskell, M., Al-Azzawi, F., Garner, R. C., Boocock, D. J., Mattock, E., Pring, D. W., Dingley, K., Turteltaub, K. W., Smith, L. L., and White, I. N. (2003) Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res. 63, 8461-8465.
34. Carmichael, P. L., Ugwumadu, A. H., Neven, P., Hewer, A. J., Poon, G. K., and Phillips, D. H. (1996) Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res. 56, 1475-1479.
35. 32P-postlabeling for tamoxifen-DNA adducts in the human endometrium. Carcinogenesis 20, 339-342.
36. 32P-postlabeling analyses of tamoxifen-DNA adducts in humans. J. Natl. Cancer Inst. 96, 1099-1104.
37. Phillips, D. H., Hewer, A., Grover, P. L., Poon, G. K., and Charmichael, P. L. (1996) Tamoxifen dose not form detectable in white blood cells of breast cancer patients. Carcinogenesis 17, 1149-1152.
38. Bartsch, H., Phillips, D. H., Nair, J., Hewer, A., Meyberg-Solomeyer, G., and Grischke, E. M. (2000) Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients. Carcinogenesis 21, 845-847.
39. Umemoto, A., Monden, Y., Lin, C.-X., Momen, M. A., Ueyama, Y., Komaki, K., Laximi, Y. R. S., and Shibutani, S. (2004) Determination of tamoxifen-DNA adducts in leukocytes from breast cancer patients treated with tamoxifen. Chem. Res. Toxicol. 17, 1577-1583.
40. Shibutani, S., Ravindernath, A., Terashima, I., Suzuki, N., Santosh, L. Y. R., Kanno, Y., Suzuki, M., Apak, T. I., Sheng, J. J., and Duffel, M. W. (2001) Mechanism of lower genotoxicity of toremifene compared with tamoxifen. Cancer Res. 61, 3925-3931.
41. Umemoto, A., Kajikawa, A., Tanaka, M., Hamada, K., Seraj, M. J., Kubota, A., Nakamura, M., Kinouchi, T., Ohnishi, Y., Yamashita, K., and Monden, Y. (1994) Presence of mucosa-specific DNA adduct in human colon: Possible implication for colorectal cancer. Carcinogenesis 15, 901-905.
42. 32P-postlabeling test for structurally diverse DNA adducts. Carcinogenesis 7, 1543-1551.
43. 32P-postlabeling. Carcinogenesis 12, 1181-1186.
44. Sridar, C., Kent, U. M., Notley, L. M., Gillam, E. M., and Hollenberg, P. F. (2002) Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J. Pharmacol. Exp. Ther. 301, 945-952.
45. Boocock, D. J., Brown, K., Gibbs, A. H., Sanchez, E., Turteltaub, K. W., and White, I. N. (2002) Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 23, 1897-1901.
46. Osborne, M. R., Hewer, A., Hardeastle, I. R., Carmichael, P. L., and Phillips, D. H. (1996) Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res. 56, 66-71.
47. Dasaradhi, L., and Shibutani, S. (1997) Identification of tamoxifen-DNA adducts formed by α-sulfate tamoxifen and α-acetoxytamoxifen. Chem. Res. Toxicol. 10, 189-196.
48. Kim, S. Y., Suzuki, N., Santosh Laxmi, Y. R., Rieger, R., and Shibutani, S. (2003) α-Hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chem. Res. Toxicol. 16, 1138-1144.
49. Shibutani, S., Dasaradhi, L., Terashima, I., Banoglu, E., and Duffel, M. W. (1998) α-Hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer Res. 58, 647-653.
50. Shibutani, S., Shaw, P., Suzuki, N., Dasaradhi, L., Duffel, M. W., and Terashima, I. (1998) Sulfation of α-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen DNA adducts. Carcinogenesis 19, 2007-2011.